Characteristics and safety outcomes of rheumatoid arthritis patients treated with AMGEVITA^® in the United Kingdom using data from a national register.

IF 4.6 2区医学 Q1 Medicine

Arthritis Research & Therapy Pub Date : 2026-04-21 DOI:10.1186/s13075-026-03807-9

Argentina E Servin, Mark Lillie, Ran Jin, Laura C Coates, Michele Brunori, Latha Krishnamoorthy, Neil Accortt, Frances Humby

引用次数: 0

查看原文本刊更多论文

在英国使用AMGEVITA®治疗类风湿关节炎患者的特征和安全性结果，数据来自国家登记。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Arthritis Research & Therapy RHEUMATOLOGY-

CiteScore

8.60

自引率

2.00%

发文量

261

审稿时长

14 weeks

期刊介绍： Established in 1999, Arthritis Research and Therapy is an international, open access, peer-reviewed journal, publishing original articles in the area of musculoskeletal research and therapy as well as, reviews, commentaries and reports. A major focus of the journal is on the immunologic processes leading to inflammation, damage and repair as they relate to autoimmune rheumatic and musculoskeletal conditions, and which inform the translation of this knowledge into advances in clinical care. Original basic, translational and clinical research is considered for publication along with results of early and late phase therapeutic trials, especially as they pertain to the underpinning science that informs clinical observations in interventional studies.

Characteristics and safety outcomes of rheumatoid arthritis patients treated with AMGEVITA® in the United Kingdom using data from a national register.

Characteristics and safety outcomes of rheumatoid arthritis patients treated with AMGEVITA^® in the United Kingdom using data from a national register.